WX [WuXi PharmaTech (Cayman)] 6-K: (Original Filing)
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
WX [WuXi PharmaTech (Cayman)] 6-K: WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3
[WuXi PharmaTech (Cayman) Inc. Form 6-K Page 3 4 2 WuXi PharmaTech (Cayman) Inc. Edward Hu Chief Financial Officer 3]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13G: (Original Filing)
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities that]
SKBI [SKYSTAR BIO-PHARMACEUTICAL CO] SC 13G: reporting person’s initial filing on this form with
[reporting person's initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page. The information required in the remainder of this cover page shall not be deemed to be filed for the purpose of Section 18 of the Securities that]
BSPM [Biostar Pharmaceuticals] S-8: (Original Filing)
[Registration No. 333- FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue, Xianyang, Shaanxi Province, People’s Republic of China 712046 Biostar Pharmaceuticals, Inc. 2013 Equity Incentive Plan (Full title of the plan) Ronghua Wang President and Chief] [BIOSTAR PHARMACEUTICALS, INC. 2013 EQUITY INCENTIVE PLAN, INC. ______________________ Section 1. Purpose. The purpose of the Biostar Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the “Plan”) is to attract and retain outstanding individuals as Key Employees, Directors and Consultants of the Company and its Subsidiaries, to recognize the contributions made to the Company and its Subsidiaries by Key Employees, Directors and] [[Schiff Hardin LLP Letterhead] July 17, 2014 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China Ladies and Gentlemen: EX-5.1 3 ex5-1.htm EX-5.1] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 dated July 17, 2014 of Biostar Pharmaceuticals, Inc. of our report dated March 31, 2014 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K]
BSPM [Biostar Pharmaceuticals] S-8: Registration No. 333- FORM S-8 REGISTRATION STATEMENT UNDER
[Registration No. 333- FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Biostar Pharmaceuticals, Inc. Maryland (State or other jurisdiction of incorporation or organization) 20-5101287 (I.R.S. Employer Identification No.) No. 588 Shiji Xi Avenue, Xianyang, Shaanxi Province, People’s Republic of China 712046 Biostar Pharmaceuticals, Inc. 2013 Equity Incentive Plan (Full title of the plan) Ronghua Wang President and Chief] [BIOSTAR PHARMACEUTICALS, INC. 2013 EQUITY INCENTIVE PLAN, INC. ______________________ Section 1. Purpose. The purpose of the Biostar Pharmaceuticals, Inc. 2013 Equity Incentive Plan (the “Plan”) is to attract and retain outstanding individuals as Key Employees, Directors and Consultants of the Company and its Subsidiaries, to recognize the contributions made to the Company and its Subsidiaries by Key Employees, Directors and] [[Schiff Hardin LLP Letterhead] July 17, 2014 Biostar Pharmaceuticals, Inc. No. 588 Shiji Xi Avenue Xianyang, Shaanxi Province People’s Republic of China Ladies and Gentlemen: EX-5.1 3 ex5-1.htm EX-5.1] [CONSENT OF INDEPENDENT REGISTERED ACCOUNTING FIRM To the Board of Directors of Biostar Pharmaceuticals, Inc. We hereby consent to the incorporation by reference in the Registration Statement on Form S-8 dated July 17, 2014 of Biostar Pharmaceuticals, Inc. of our report dated March 31, 2014 relating to the consolidated financial statements, which appears in the Annual Report on Form 10-K]
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Schedules 2014 Annual Meeting of Shareholders BEIJING, July 14, 2014 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District,] [July 15, 2014 Dear Shareholder: You are cordially invited to attend the 2014 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on August 27, 2014, at 9:00 A.M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China. At this year’s annual meeting, you will be asked to: · approve the] []
SVA [SINOVAC BIOTECH] 6-K: Sinovac Schedules 2014 Annual Meeting of Shareholders BEIJING,
[Sinovac Schedules 2014 Annual Meeting of Shareholders BEIJING, July 14, 2014 -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, announced today that it will hold its 2014 Annual Meeting of Shareholders on Wednesday, August 27, 2014 at 9:00 a.m. Beijing Time. The meeting will be held at No. 39 Shangdi Xi Road, Haidian District,] [July 15, 2014 Dear Shareholder: You are cordially invited to attend the 2014 annual meeting of shareholders of Sinovac Biotech Ltd. to be held on August 27, 2014, at 9:00 A.M. Beijing time, at No. 39 Shangdi Xi Road, Haidian District, Beijing 100085, People’s Republic of China. At this year’s annual meeting, you will be asked to: · approve the] []
SVA [SINOVAC BIOTECH] 6-K: (Original Filing)
[Sinovac Announces Favorable Reduction in Value Added Tax Rate BEIJING, June 25, 2014 /PRNewswire/ -- Sinovac Biotech Ltd. (NASDAQ: SVA), a leading provider of biopharmaceutical products in China, today announced that the value added tax (or "VAT") rate applied to the sales of Sinovac's vaccine products will be reduced to 3% from the current rate of 6%, according to a] []
